NCT04641442 - Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

October 14, 2025

Study Completion Date

September 11, 2027

Conditions

NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

Interventions

BIOLOGICAL

MAS825

Experimental drug

BIOLOGICAL

Placebo

matching placebo

Trial Locations (21)

19104

Children´s Hospital of Philadelphia, Philadelphia

28046

Novartis Investigative Site, Madrid

45229

Cincinnati Children's Hospital, Cincinnati

Cincinnati Childrens Hospital, Cincinnati

75970

Novartis Investigative Site, Paris

77030

Texas Childrens Hospital, Houston

Texas Children´s Hospital, Houston

98105

Seattle Childrens Hospital, Seattle

Seattle Children´s Hospital, Seattle

19104-4399

Childrens Hospital of Philadelphia, Philadelphia

121 00

Centrum detske revmatologie a autoinflamatornich onemocneni, Prague

128 08

Novartis Investigative Site, Prague

150 06

Novartis Investigative Site, Prague

Ustav Imunologie 2 LF UK a FN Motol, Prague

00165

Bambino Gesu Hospital, Roma

Novartis Investigative Site, Roma

266-0007

Novartis Investigative Site, Chiba

08036

Hospital Clinic Barcelona, Barcelona

NW3 2QG

Novartis Investigative Site, London

WC1N 3JH

Great Ormond Street Hospital, London

Novartis Investigative Site, London